Immuno-virological status and its associated factors among HIV-positive patients receiving highly active antiretroviral therapy at delgi primary hospital, northwest Ethiopia, 2020/2021: A cross-sectional study

Background: Highly active antiretroviral therapy (HAART) improves clinical outcomes by suppressing viral replication and allowing immune reconstitution. It also reduces HIV-related complications including morbidity, mortality, and extended hospitalizations for HIV-positive individuals. Regular asses...

Full description

Bibliographic Details
Main Authors: Teklehaimanot Kiros, Abebe Taye, Lemma Workineh, Tahir Eyayu, Shewaneh Damtie, Wasihun Hailemichael, Tegenaw Tiruneh
Format: Article
Language:English
Published: Elsevier 2022-08-01
Series:Heliyon
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844022014578
_version_ 1811188025236914176
author Teklehaimanot Kiros
Abebe Taye
Lemma Workineh
Tahir Eyayu
Shewaneh Damtie
Wasihun Hailemichael
Tegenaw Tiruneh
author_facet Teklehaimanot Kiros
Abebe Taye
Lemma Workineh
Tahir Eyayu
Shewaneh Damtie
Wasihun Hailemichael
Tegenaw Tiruneh
author_sort Teklehaimanot Kiros
collection DOAJ
description Background: Highly active antiretroviral therapy (HAART) improves clinical outcomes by suppressing viral replication and allowing immune reconstitution. It also reduces HIV-related complications including morbidity, mortality, and extended hospitalizations for HIV-positive individuals. Regular assessment for antiretroviral treatment response is fundamentally important to address the factors associated with the poor clinical outcome including immunologic failures among HIV-positive patients on HAART. Therefore, this study aimed to investigate the immuno-virological status and describe its determinants among HIV-positive patients receiving HAART at Delgi primary hospital, Northwest Ethiopia. Methods: A hospital-based cross-sectional study was conducted at Delgi primary hospital from October 25th through June 19th 2021 among a total of 442 study participants. A systematic random sampling technique was employed to enrol participants in the study. Socio-demographic and clinically related data were collected using a semi-structured questionnaire. About 3–5 ml of venous blood was collected aseptically for CD4+ T cell count and viral load test. SPSS version 20 software was used for statistical analysis. Bivariate and multivariate logistic regression analyses were conducted to determine the factors associated with immuno-virologic status among HIV-positive patients on HAART. The odds ratio with 95% CI was computed to determine the strength of association. Then, a p-value < 0.05 was considered a statistically significant association. For this study, the results were presented by using frequency summary tables, and texts. Results: Among the total study participants, 283 (64%) were males and the mean age of the study participants was 37 ± 11.5. The overall immunological and virological failure among highly active antiretroviral therapy (HAART) receiving participants was found to be 9.5% (42/442, 95%CI:3.23–15.09) and 12.2% (54/442, 95% CI: 2.81–23.04) respectively. In the multivariate analysis, study participants with age ≥50 years old [AOR = 1.97, p = 0.01, 95%CI (0.02–4.03)], participants having current viral load count greater ≥1000 copies/ml [AOR = 3.97, p = 0.03, 95%CI (1.09–5.01)] and having TB-co-infection [AOR = 2.51, p = 0.05, 95%CI (1.02–7.51)] were statistically associated with increased risk of immunological failure. Similarly, TB-coinfected participants were 1.88 (95%CI = 0.89–10.02) times at greater risk for virological failure. Conclusion: In this study, the magnitude of immuno-virological failure is alarming. This may be shown the need for integrated and substantial commitment to enhancing patient antiretroviral treatment adherence in the study area. Also, regular assessment for antiretroviral treatment response is fundamentally important to address the determinants associated with virological and immunologic failures among HIV-positive patients taking HAART. Furthermore, early initiation of HAART may be imperative to achieve favourable virological suppression and immunological reconstitution.
first_indexed 2024-04-11T14:13:35Z
format Article
id doaj.art-7c363539586848568b635c1f49ee2432
institution Directory Open Access Journal
issn 2405-8440
language English
last_indexed 2024-04-11T14:13:35Z
publishDate 2022-08-01
publisher Elsevier
record_format Article
series Heliyon
spelling doaj.art-7c363539586848568b635c1f49ee24322022-12-22T04:19:37ZengElsevierHeliyon2405-84402022-08-0188e10169Immuno-virological status and its associated factors among HIV-positive patients receiving highly active antiretroviral therapy at delgi primary hospital, northwest Ethiopia, 2020/2021: A cross-sectional studyTeklehaimanot Kiros0Abebe Taye1Lemma Workineh2Tahir Eyayu3Shewaneh Damtie4Wasihun Hailemichael5Tegenaw Tiruneh6Corresponding author.; Department of Medical Laboratory Sciences, College of Health Sciences and School of Medicine, Debre Tabor University, Debre Tabor, EthiopiaDepartment of Medical Laboratory Sciences, College of Health Sciences and School of Medicine, Debre Tabor University, Debre Tabor, EthiopiaDepartment of Medical Laboratory Sciences, College of Health Sciences and School of Medicine, Debre Tabor University, Debre Tabor, EthiopiaDepartment of Medical Laboratory Sciences, College of Health Sciences and School of Medicine, Debre Tabor University, Debre Tabor, EthiopiaDepartment of Medical Laboratory Sciences, College of Health Sciences and School of Medicine, Debre Tabor University, Debre Tabor, EthiopiaDepartment of Medical Laboratory Sciences, College of Health Sciences and School of Medicine, Debre Tabor University, Debre Tabor, EthiopiaDepartment of Medical Laboratory Sciences, College of Health Sciences and School of Medicine, Debre Tabor University, Debre Tabor, EthiopiaBackground: Highly active antiretroviral therapy (HAART) improves clinical outcomes by suppressing viral replication and allowing immune reconstitution. It also reduces HIV-related complications including morbidity, mortality, and extended hospitalizations for HIV-positive individuals. Regular assessment for antiretroviral treatment response is fundamentally important to address the factors associated with the poor clinical outcome including immunologic failures among HIV-positive patients on HAART. Therefore, this study aimed to investigate the immuno-virological status and describe its determinants among HIV-positive patients receiving HAART at Delgi primary hospital, Northwest Ethiopia. Methods: A hospital-based cross-sectional study was conducted at Delgi primary hospital from October 25th through June 19th 2021 among a total of 442 study participants. A systematic random sampling technique was employed to enrol participants in the study. Socio-demographic and clinically related data were collected using a semi-structured questionnaire. About 3–5 ml of venous blood was collected aseptically for CD4+ T cell count and viral load test. SPSS version 20 software was used for statistical analysis. Bivariate and multivariate logistic regression analyses were conducted to determine the factors associated with immuno-virologic status among HIV-positive patients on HAART. The odds ratio with 95% CI was computed to determine the strength of association. Then, a p-value < 0.05 was considered a statistically significant association. For this study, the results were presented by using frequency summary tables, and texts. Results: Among the total study participants, 283 (64%) were males and the mean age of the study participants was 37 ± 11.5. The overall immunological and virological failure among highly active antiretroviral therapy (HAART) receiving participants was found to be 9.5% (42/442, 95%CI:3.23–15.09) and 12.2% (54/442, 95% CI: 2.81–23.04) respectively. In the multivariate analysis, study participants with age ≥50 years old [AOR = 1.97, p = 0.01, 95%CI (0.02–4.03)], participants having current viral load count greater ≥1000 copies/ml [AOR = 3.97, p = 0.03, 95%CI (1.09–5.01)] and having TB-co-infection [AOR = 2.51, p = 0.05, 95%CI (1.02–7.51)] were statistically associated with increased risk of immunological failure. Similarly, TB-coinfected participants were 1.88 (95%CI = 0.89–10.02) times at greater risk for virological failure. Conclusion: In this study, the magnitude of immuno-virological failure is alarming. This may be shown the need for integrated and substantial commitment to enhancing patient antiretroviral treatment adherence in the study area. Also, regular assessment for antiretroviral treatment response is fundamentally important to address the determinants associated with virological and immunologic failures among HIV-positive patients taking HAART. Furthermore, early initiation of HAART may be imperative to achieve favourable virological suppression and immunological reconstitution.http://www.sciencedirect.com/science/article/pii/S2405844022014578Immunological responseHIVVirological failureHAARTPredictorsCD4+ T cell count
spellingShingle Teklehaimanot Kiros
Abebe Taye
Lemma Workineh
Tahir Eyayu
Shewaneh Damtie
Wasihun Hailemichael
Tegenaw Tiruneh
Immuno-virological status and its associated factors among HIV-positive patients receiving highly active antiretroviral therapy at delgi primary hospital, northwest Ethiopia, 2020/2021: A cross-sectional study
Heliyon
Immunological response
HIV
Virological failure
HAART
Predictors
CD4+ T cell count
title Immuno-virological status and its associated factors among HIV-positive patients receiving highly active antiretroviral therapy at delgi primary hospital, northwest Ethiopia, 2020/2021: A cross-sectional study
title_full Immuno-virological status and its associated factors among HIV-positive patients receiving highly active antiretroviral therapy at delgi primary hospital, northwest Ethiopia, 2020/2021: A cross-sectional study
title_fullStr Immuno-virological status and its associated factors among HIV-positive patients receiving highly active antiretroviral therapy at delgi primary hospital, northwest Ethiopia, 2020/2021: A cross-sectional study
title_full_unstemmed Immuno-virological status and its associated factors among HIV-positive patients receiving highly active antiretroviral therapy at delgi primary hospital, northwest Ethiopia, 2020/2021: A cross-sectional study
title_short Immuno-virological status and its associated factors among HIV-positive patients receiving highly active antiretroviral therapy at delgi primary hospital, northwest Ethiopia, 2020/2021: A cross-sectional study
title_sort immuno virological status and its associated factors among hiv positive patients receiving highly active antiretroviral therapy at delgi primary hospital northwest ethiopia 2020 2021 a cross sectional study
topic Immunological response
HIV
Virological failure
HAART
Predictors
CD4+ T cell count
url http://www.sciencedirect.com/science/article/pii/S2405844022014578
work_keys_str_mv AT teklehaimanotkiros immunovirologicalstatusanditsassociatedfactorsamonghivpositivepatientsreceivinghighlyactiveantiretroviraltherapyatdelgiprimaryhospitalnorthwestethiopia20202021acrosssectionalstudy
AT abebetaye immunovirologicalstatusanditsassociatedfactorsamonghivpositivepatientsreceivinghighlyactiveantiretroviraltherapyatdelgiprimaryhospitalnorthwestethiopia20202021acrosssectionalstudy
AT lemmaworkineh immunovirologicalstatusanditsassociatedfactorsamonghivpositivepatientsreceivinghighlyactiveantiretroviraltherapyatdelgiprimaryhospitalnorthwestethiopia20202021acrosssectionalstudy
AT tahireyayu immunovirologicalstatusanditsassociatedfactorsamonghivpositivepatientsreceivinghighlyactiveantiretroviraltherapyatdelgiprimaryhospitalnorthwestethiopia20202021acrosssectionalstudy
AT shewanehdamtie immunovirologicalstatusanditsassociatedfactorsamonghivpositivepatientsreceivinghighlyactiveantiretroviraltherapyatdelgiprimaryhospitalnorthwestethiopia20202021acrosssectionalstudy
AT wasihunhailemichael immunovirologicalstatusanditsassociatedfactorsamonghivpositivepatientsreceivinghighlyactiveantiretroviraltherapyatdelgiprimaryhospitalnorthwestethiopia20202021acrosssectionalstudy
AT tegenawtiruneh immunovirologicalstatusanditsassociatedfactorsamonghivpositivepatientsreceivinghighlyactiveantiretroviraltherapyatdelgiprimaryhospitalnorthwestethiopia20202021acrosssectionalstudy